BIO-GENE - Key Persons

Alex was a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia list, and has over 25 years of experience as a corporate lawyer.

Job Titles:

• Adviser to the BGT Board
• Chairman of Rathbone Wine Group

Doug has been Advisor at Bio-Gene since December 2017. He is a former Managing Director of Nufarm, a position he held for more than 15 years during which time he successfully transformed Nufarm to become one of the world's leading crop protection and seed companies with an extensive global footprint. He has more than 40 years' experience, with expertise in specific functional areas and has chemical engineering and commerce background. Doug serves as the Chairman of Rathbone Wine Group, Director of Cotton Seed Distributors, AgBiTech, Delta Agribusiness and Go Resources Pty Ltd. He is also a Member of the Rabo Bank Advisory Board.

Job Titles:

• Program Manager

James was educated in the UK, obtaining a bachelor's degree in Biological Science (University of Salford, UK) and a Master's degree (with distinction) in Molecular Parasitology and Entomology (University of Manchester, UK). This training provided a strong understanding of contemporary studies relating to research into the immunological and molecular aspects of selected parasites and vector/parasite relationships. A specific emphasis was placed on the epidemiology and control of vectors of known economic importance and their impacts on the public, animal and agricultural sectors. After completing a PhD in cell and developmental biology in 2008, James was employed as a Science and Technology Program Manager for a world leading European-based agribusiness holding company (EW-Group). In this role he was responsible for a global program of collaborative research projects which aimed to improve company process efficiencies. In 2015 James joined a subsidiary of the EW-Group (Aviagen Ltd) as Research/Technical Development Manager (an EW-Group owned company). Here he assisted in leading a broad range of research initiatives aimed at improving the understanding of Aviagen's products, processes, and developing best-practice advice for customers. This involved cross cultural and geographical collaborations with private industry, leading academic institutions and government organisations. This role saw James gain further experience in the coordination multiple cross disciplinary research projects in order to develop new technologies and methods that would add value to the Aviagen business. As part of this role he was responsible for the management of company trials infrastructure, the management, analysis and interpretation of product and research and development trials run internally or in external facilities across Europe. This role delivered multiple research outputs and technical support internally to the company, customer and wider audiences. James was appointed as Program Manager for R&D within Bio-Gene in December 2018.

Job Titles:

• Scientific Advisory Board Member

Peter has over 30 years of experience in the bio-agriculture community, with a passion for moving technology to commercial application. He is currently the CEO of Cibus Global, LLC. As co-founder of Cibus, he has taken a lead role in developing the core gene editing technologies associated with the proprietary Rapid Trait Development System (RTDS™). Prior to taking on the CEO position at Cibus in 2014, Peter led the research and product development teams since the inception of the company in 2001. Peter has spent more than three decades in agricultural research, with direct experience in areas including plant biotechnology, precision gene-editing and the applications of novel breeding technologies. Early in his career he was also involved in the introduction of improved root crops to many countries in Southeast Asia and the South Pacific. Peter was employed by the Victorian Department of Agriculture and Rural Affairs (DARA) in Australia from 1985 to 1992. He served as a Scientific Officer based at the Plant Research Institute (PRI), working with research groups throughout Southeast Asia and the South Pacific. As part of the plant virology group at Queensland University of Technology (QUT), he worked on the molecular biology of banana bunch top virus (BBTV) and the development of transgenes for pathogen-derived resistance. He continued his research as a postdoctoral scientist at the Boyce Thompson Institute at Cornell University, where he was one of the pioneers of the early work that led to the Cibus Rapid Trait Development System (RTDS) technology. Prior to joining Cibus, he was Research Director of the Plant and Industrial Products Division at ValiGen, formerly Kimeragen, Inc. At Cibus he has led the scientific and regulatory endeavours that have led to the launching of Cibus' first products in USA. More recently (2014) he assumed the role of President and CEO of Cibus tasked with taking Cibus to the next level of growth as a growth stage commercial company leading the way for licensing of gene edited traits to leading global seed companies. Peter received his Ph.D. in Plant Molecular Virology from QUT in Brisbane, Australia and is a BSc (Hons) graduate of Monash University, Melbourne, Australia. Dr Beetham has authored many scientific publications including the pioneering publications for gene-editing starting in1999. He has also been a leading author on over 100 patents and patent applications.

Edmond has over thirty years' experience working as a senior executive across multiple industries in both public and private enterprises, and with particular interest in process re-engineering and business turnarounds. Prior to joining Bio-Gene, Edmond was CFO/CoSEC of SECOS Group Limited (which is listed on the ASX), CFO/CoSec of Q Technology Group Limited (also ASX listed), and Asia Pacific Controller of ASSA ABLOY, a Swedish multinational, where he was involved heavily in their merger and acquisition activities. Edmond has a B.A and B. Bus (Hon) from the University of Windsor, Canada, a Graduate Diploma in Accounting from Monash University, and is a Member of CPA Australia.

Job Titles:

• Chemistry & Manufacturing Consultant

Neil is an experienced Industrial Chemist, who has been employed by Monsanto for more than 40 years. He is a specialist in formulation development, production and process management. Neil is also qualified for manufacturing plant audits, quality and environmental management.

Job Titles:

• Professor of Entomology at Purdue University
• Scientific Advisory Board Member

Catherine is a Professor of Entomology at Purdue University. She was part of an internationally recognised medical entomology research program focusing on the biology and control of arthropod vectors (e.g., mosquitoes, sand flies and ticks) that transmit diseases to humans and animals. Together with collaborators, she created the Purdue Insecticide Discovery Pipeline (PIDP) that employs an innovative, target-based approach for the discovery and development of novel mode of action insecticides that have limited effects on non-pest species. She is the recipient of numerous awards, including the President's Fellow for the Life Sciences, and is a Showalter Faculty Scholar.

Job Titles:

• Global Regulatory Affairs Lead
• Head of Regulatory

Sarah was educated in Belgium obtaining a Master's degree (with distinction) in Agricultural engineering focus biotechnology (Free University Brussels). After completing her Masters, Sarah worked for more then 10 years at the world leading Agri company Monsanto (and subsequently Bayer after the Monsanto acquisition). Her main areas of focus were product registration for agricultural and consumer products across major geographic jurisdictions. She gained invaluable knowledge and experience working with key stakeholders (including regulators and industry associations) and achieved notable success, especially in the European regulatory system. Sarah has worked cross functional and has broad experience in working closely together with R&D, legal, manufacturing, supply and sales teams. In early 2021 Sarah joined Pelsis a global pest control technology company as Head of Regulatory, with a focus on leading and coaching a team in developing and implementing regulatory strategies for biocide consumer and professional products. In late 2021, Sarah relocated with her family permanently to Brisbane, Australia. Sarah brings an advanced level of technical and regulatory expertise that will enable Bio-Gene to manage the registration process of Flavocide™ and Qcide™ as efficiently as possible. Her experience with different regulatory bodies around the world is invaluable, and her command of multiple languages ensures good communication between Bio-Gene, our commercial partners, our registration study providers, and the various government regulatory bodies. Sarah was appointed as Head of Regulatory affairs within Bio-Gene in February 2022.

Job Titles:

• Chemistry )

Tim brings more than 30 years' experience and expertise to Bio-Gene, with a successful track record of delivering growth in the agtech, food and human health sectors. Tim has deep multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance. As a hands-on leader, Tim has held several key executive roles, specialising in product development and expanding business partnerships. As CEO of SIRA Pty Ltd, Tim led the commercial development of technologies to produce new types of healthier sugar. Prior to this, Tim was the CEO of Dimerix BioScience Pty Ltd, a venture capital-funded medicinal drug discovery and development company, where he managed the development of a novel treatment for diabetic nephropathy and the company completed three substantial pharmaceutical partnering deals within 12 months and significantly expanded its investor base. Tim also has extensive listed company experience, including with pharmaceutical development company, Starpharma (ASX:SPL), where he worked to steer it through the IPO process and establishing several commercial relationships globally. Most recently, Tim has been consulting to companies in the health and medical technology sectors in Australia, providing strategic, government and regulatory advice. Tim holds a Bachelor of Law and a Bachelor of Science, majoring in chemistry, from the University of Melbourne.